BioNTech SE is 2.6x more valuable than HALOZYME THERAPEUTICS, INC. by market capitalization ($21.79 B vs $8.36 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | HALO | BNTX |
|---|---|---|
| Market cap | $8.36 B | $21.79 B |
| US-listed rank | #1040 | #587 |
| Revenue (latest FY) | $1.40B | - |
| Net income (latest FY) | $316.89M | - |
| Net margin | 22.7% | - |
| P/E (trailing FY) | 26.4 | - |
| SEC filings | 1,481 | 548 |
BioNTech SE is 2.6x more valuable than HALOZYME THERAPEUTICS, INC. by market capitalization ($21.79 B vs $8.36 B).
Full pages: HALOZYME THERAPEUTICS, INC. and BioNTech SE, or browse the full rankings.